...
机译:边缘可重型胰腺癌:需要标准化和方法,用于最佳临床试验设计
Department of Surgical Oncology University of Texas MD Anderson Cancer Center Houston TX United;
Department of Medicine Northshore University Health System University of Chicago Chicago IL;
Department of Radiation Oncology Johns Hopkins University Baltimore MD United States;
Department of Health Science Research Mayo Clinic Rochester MN United States;
Department of Medicine University of California at San Francisco San Francisco CA United States;
Department of Medicine University of California at San Francisco San Francisco CA United States;
Department of Medicine University of Chicago Chicago IL United States;
Department of Medical Oncology Mayo Clinic Rochester MN United States;
Department of Medical Oncology Karmanos Medical Center Detroit MI United States;
Division of Surgical Oncology Department of Surgery University of California at San Diego San;
Department of Surgical Oncology University of Texas MD Anderson Cancer Center Houston TX United;
Department of Surgery University of Chicago Chicago IL United States;
Department of Medicine Vanderbilt University Nashville TN United States;
Department of Surgery University of Cincinnati Medical Center Cincinnati OH United States;
机译:边界可切除的胰腺癌:需要标准化和最佳临床试验设计方法
机译:术前改良FOLFIRINOX治疗,随后以卡培他滨为基础的化学放疗用于边界可切除胰腺癌肿瘤临床试验的临床联盟A021101
机译:Neoadjuvant Folfirinox总基于Neoadjuvant Gemcitabine的化学疗法和佐剂吉西他滨,用于可切除和边界可重型的胰腺癌(Preopanc-2试验):用于全国多中心随机对照试验的研究方案
机译:边缘可重型胰腺癌
机译:针对边缘可切除胰腺癌病变的VMAT,IMRT和质子治疗技术的剂量学评估
机译:可能切除胰腺癌:极品标准化和方法优化临床试验设计
机译:可切除和边缘可切除胰腺癌的术前放化疗与即刻手术(PREOPANC试验):一项多中心随机对照试验的研究方案